Status:
COMPLETED
Effect of Dexmedetomidine on Central Nervous System Complications in Patients Undergoing Cardiac Surgery
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Randomized Controlled Trial
Dexmedetomidine
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
With the continuous improvement of medical technology, more and more patients need to undergo surgery as a kind of treatment for their diseases. However, there are various pains that may occur in the ...
Detailed Description
1. Observing the effect of intraoperative use of dexmedetomidine on the incidence of postoperative anxiety and depression in patients undergoing cardiac surgery; 2. Observe the effects of intraoperati...
Eligibility Criteria
Inclusion
- Age range from 18 to 85 years old, regardless of gender
- Patients who undergo cardiac surgery on a scheduled basis;
- ASA level 1-4;
- Obtain written informed consent form;
Exclusion
- Patients with MMSE scores less than 18 or dementia, intellectual disability, and inability to communicate (coma, severe dementia, hearing or language impairment);
- Have a history of mental or neurological disorders (such as schizophrenia, epilepsy, Parkinson's disease, or severe myasthenia gravis);
- Previous history of brain injury;
- Severe liver dysfunction (Child pugh C-grade) or renal insufficiency (preoperative dialysis);
- Severe bradycardia (heart rate below 50 beats per minute), pathological sinus syndrome, or atrioventricular block without a pacemaker;
- Postoperative intensive care unit (ICU) duration exceeding 7 days or death;
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06551259
Start Date
January 1 2024
End Date
August 30 2024
Last Update
September 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China